News & Videos - SURMODICS INC.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences: The Needham Virtual MedTech & Diagnostics 1x1 Conference , which is being held from August 14‑15, 2023. Management will participate in 1x1 meetings with investors on Monday, August 14. There will be no formal presentation. The Sidoti Micro Cap Virtual Conference ,...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023. Third Quarter Fiscal 2023 Financial Summary Total Revenue of $52.5 million, an increase of 111% year-over-year Recognized $24.6 million in license fee revenue upon receipt of a $27.0 million milestone payment...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that third quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, August 2. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, August 2, to discuss the third quarter of fiscal 2023 financial results and accomplishments, and to host a question-and-answer...

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the receipt of U.S. Food and Drug Administration (FDA) approval for the SurVeil™ drug-coated balloon (DCB). The SurVeil DCB may now be marketed and sold in the U.S. to physicians for percutaneous transluminal angioplasty, after appropriate vessel preparation, of de novo or restenotic lesions (≤ 180 mm in length) in femoral and popliteal...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ LP (Low Profile) Thrombectomy System. Introduced in 2021, the Pounce Thrombectomy System is intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature in vessels 3.5 mm to 6 mm in diameter. The Pounce LP Thrombectomy System, a new addition to the...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9, 2023. Management will present on Thursday, June 8, at 1:30 p.m. ET (12:30 p.m. CT). A live webcast of the presentation can be accessed by going to “Events & Presentations” under the “Investors” section of the...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023. Second Quarter Fiscal 2023 Financial Summary Total Revenue of $27.2 million, an increase of 4% year-over-year GAAP Diluted EPS of $(0.55), compared to $(0.29) in the prior-year period Non-GAAP Diluted EPS...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounce™ Thrombectomy System Retrospective Registry. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce system for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. The registry will collect real-world efficacy and safety outcomes data for endovascular...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, April 26, to discuss the second quarter of fiscal 2023 financial results and accomplishments, and to host a...

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Ankur Lodha, Lafayette, La., and Dr. Pradeep Nair, Houma, La., are the first physicians to use the company’s Sublime™ radial access microcatheter. Drs. Lodha and Nair are interventional cardiologists at the Cardiovascular Institute of the South. The Sublime microcatheter is in limited market evaluation. The full suite of Sublime...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023. Management will present on Thursday, April 20, at 10:15 a.m. ET (9:15 a.m. CT). A live webcast of the presentation can be accessed by going to “Events & Presentations” under the “Investors” section of the...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX PR Newswire NEW YORK, March 31, 2023 NEW YORK , March 31, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading business information to the investing...

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it has received formal feedback from the Food and Drug Administration (FDA; the Agency) related to its proposed approach to submit an amended premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB). Following the receipt of the FDA letter announced in the company’s press release on January 19th, Surmodics has been...

ROSEN, A LEADING LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX PR Newswire NEW YORK, March 17, 2023 NEW YORK , March 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading business information to the investing public. SO...

SRDX INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX PR Newswire NEW YORK, March 10, 2023 NEW YORK , March 10, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading business information...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences: The 33rd Oppenheimer Annual Healthcare Conference , which is being held virtually March 13‑15, 2023. Management will present on Wednesday, March 15, at 10:40 a.m. ET (9:40 a.m. CT). The Sidoti Small-Cap Conference , which is being held virtually March 22-23, 2023....

NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX PR Newswire NEW YORK, March 1, 2023 NEW YORK , March 1, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading business information to the investing...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX PR Newswire NEW YORK, Feb. 22, 2023 NEW YORK , Feb. 22, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. ("Surmodics" or the "Company") (NASDAQ: SRDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Surmodics and certain of its officers...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX PR Newswire NEW YORK, Feb. 21, 2023 NEW YORK , Feb. 21, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading business information to the investing...

SRDX INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation - SRDX PR Newswire NEW YORK, Feb. 8, 2023 NEW YORK , Feb. 8, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading business information...